» Articles » PMID: 15449204

Regulation of Drug Sensitivity of Gastric Cancer Cells by Human Calcyclin-binding Protein (CacyBP)

Overview
Journal Gastric Cancer
Date 2004 Sep 28
PMID 15449204
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Calcyclin-binding protein (CacyBP) was previously identified as an upregulated gene in a multidrug-resistant gastric cancer cell line, SGC7901/ADR, compared to its parental cells, SGC7901, by subtractive hybridization. The aim of this study was to explore the role of CacyBP in multidrug resistance (MDR) in gastric cancer cells.

Methods: The cDNA encoding CacyBP was generated by reverse-transcription-polymerase chain reaction (RT-PCR), and mouse antisera against CacyBP was raised using recombinant CacyBP as the immunogen. The expression of CacyBP in gastric cancer cells was determined by Northern and Western blots. Sense and antisense vectors for CacyBP were introduced into SGC7901 and SGC7901/ADR cells, respectively. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay was performed to evaluate the drug sensitivity of gastric cancer cells. Flow cytometry was employed to determine adriamycin accumulation and retention in gastric cancer cells.

Results: Northern and Western blots demonstrated upregulation of CacyBP in SGC7901/ADR cells compared to SGC7901 cells. SGC7901-CacyBP and SGC7901/ADR-anCacyBP cells were prepared, in which CacyBP was genetically increased and decreased, respectively. As compared with SGC7901, SGC7901-CacyBP cells exhibited significantly increased ( P < 0.01) IC(50) values for vincristine, adriamycin, and 5-fluorouracil. Meanwhile, as compared with SGC7901/ADR, SGC7901/ADR-anCacyBP cells exhibited significantly decreased ( P < 0.01) IC(50) values for these three drugs. SGC7901-CacyBP and SGC7901/ADR-anCacyBP cells displayed no obvious difference ( P > 0.05) in intracellular adriamycin content compared to their corresponding parental cells.

Conclusions: Upregulation of CacyBP is associated with MDR in gastric cancer cells. CacyBP could regulate the responses of gastric cancer cells to chemotherapy. But the underlying mechanisms of CacyBP-related MDR need further identification.

Citing Articles

Identification of tumor biomarkers for pathological complete response to neoadjuvant treatment in locally advanced breast cancer.

Gopinath P, Veluswami S, Gopisetty G, Sundersingh S, Rajaraman S, Thangarajan R Breast Cancer Res Treat. 2022; 194(2):207-220.

PMID: 35597840 DOI: 10.1007/s10549-022-06617-0.


Causal Inference Network of Genes Related with Bone Metastasis of Breast Cancer and Osteoblasts Using Causal Bayesian Networks.

Park S, Chung C, Gonzalez E, Yoo C J Bone Metab. 2018; 25(4):251-266.

PMID: 30574470 PMC: 6288606. DOI: 10.11005/jbm.2018.25.4.251.


Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.

Dytfeld D, Luczak M, Wrobel T, Usnarska-Zubkiewicz L, Brzezniakiewicz K, Jamroziak K Oncotarget. 2016; 7(35):56726-56736.

PMID: 27527861 PMC: 5302948. DOI: 10.18632/oncotarget.11059.


CacyBP/SIP nuclear translocation regulates p27Kip1 stability in gastric cancer cells.

Niu Y, Li Y, Wang J, Lu Y, Liu Z, Feng S World J Gastroenterol. 2016; 22(15):3992-4001.

PMID: 27099442 PMC: 4823249. DOI: 10.3748/wjg.v22.i15.3992.


The potential role of CacyBP/SIP in tumorigenesis.

Ning X, Chen Y, Wang X, Li Q, Sun S Tumour Biol. 2016; 37(8):10785-91.

PMID: 26873490 DOI: 10.1007/s13277-016-4871-y.